🇺🇸 FDA
Pipeline program

A phase I study of [177Lu]Lu-EVS459 in patients with ovarian and lung cancers

CGIZ943A12101

Phase 1 other active

Quick answer

A phase I study of [177Lu]Lu-EVS459 in patients with ovarian and lung cancers for Advanced high-grade serous ovarian cancer (OC), Locally advanced unresectable or metastatic non-squamous non-small cell lung carcinoma (NSCLC) is a Phase 1 program (other) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Ophthalmics Europe
Indication
Advanced high-grade serous ovarian cancer (OC), Locally advanced unresectable or metastatic non-squamous non-small cell lung carcinoma (NSCLC)
Phase
Phase 1
Modality
other
Status
active

Clinical trials